No abstract

Background: Acute lymphoblastic leukemia (ALL) is a malignant disease that arises from several genetic mutations in a single B- or T-lymphoid precursor, resulting in altered blast cell survival, proliferation, and maturation. Objectives: This current study was aimed to determine the significance of aberrant CD133 and 45 expressions in Sudanese Patients with Acute lymphoblastic Leukemia, and their clinical significance in Khartoum state. Materials and Methods: One hundred Sudanese participants were enrolled in this study as follows: 88 Patients diagnosed with ALL as a case and 12 healthy controls donors were randomly selected. 2.5-5 mL of EDTA blood/bone marrow for flowcytometry from each patient and controls subject. Results: Eighty-eight newly diagnosed Sudanese patients with acute lymphocytic leukemia (ALL) were involved in this study, their age average is (15.7) and their stander deviation (SD) is 17.4. The frequency of aberrant markers concerning control groups was significantly associated with all patients in CD 45 with a P value (0.0001), while there was no difference between cases and control in the frequency of CD 133 antigen, there was no significant difference between age groups in the expression of different aberrant antigens. The study was significantly more expressed CD133 in males than females. Also no significant difference in hematological parameters between patients with or without expression of Aberrant CD 45 and 133 markers, while we found significantly high TWBCs in T. cell leukemia. Conclusion: Aberrant myeloid antigens CD45 was significantly associated with childhood and adult ALL and may be considered as important prognostic factors, while CD 133 were not associated with ALL.

Background: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. This study was prospective study conducted in Khartoum state during period from October 2018 until 2021 Objective: This study was aimed to determine the significance of the expression of CD123 in Sudanese Patients with Acute Myeloid Leukemia, and their clinical impact. Method: The study population was selected as 100 AML patients as study group. 2.5 ml of venous blood were collected and poured into ethylene di-amine tetra acidic acid (EDTA) for examination of peripheral Blood smears and complete blood count, aspirate and trephine biopsy of bone marrow were collected for smearing and staining and detected CD markers by using flow cytometry Results: The result showed that 57.6% of AML patients with positive CD123. The study was revealed insignificant difference in CD123 in correlated to age with p.value=0.509, and also insignificant difference in CD123 when correlated to gender male and female with p.value=0.705, and the result showed that CD123 expression was significant decreased in bone marrow sample compared to peripheral sample with p.value=0.019, also the finding showed that CD123 expression was strongest being in M3 subtype (56.8+36.8) with P-value (0.099). Conclusion: This study was concluded that 57.6% of AML patients were positive for CD123 and also reflect thatCD123 expression was strongest being in M3 subtype. Keyword: Acute Myeloid Leukemia, CD123 ,Sudan .